Floatz logo

Batiraxcept

Platinum-Resistant Primary Peritoneal Carcinoma

Washington University School of Medicineprotein_peptidePhase 1/2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
89/ 100

Competitive context

154 Active assets in the Platinum-Resistant Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Batiraxcept is also rated in:

ovarian cancerDormant
C
Indicative ·
39 / 100
View asset →
ovarian carcinomaDormant
C
Indicative ·
35 / 100
View asset →
fallopian tube carcinomaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →